Rett Gene Therapies Race to 2027 Readouts on Fragile Early 100% Signals

Neurogene and Taysha Gene Therapies Nearing Regulatory Submissions for Rett Syndrome

Taysha Gene Therapies and Neurogene are nearing regulatory submissions for their respective gene therapies, TSHA-102 and NGN-401, for Rett syndrome. Both companies have completed dosing in their pivotal trials, REVEAL (Taysha, 17 girls) and Embolden (Neurogene, 25 female patients), with data expected in the first and second half of 2027, respectively. These one-time treatments have demonstrated 100% response rates in ongoing early-stage trials, with patients meeting multiple developmental milestones. The Rett syndrome community holds high hopes for these gene therapies to offer a transformative, root-cause treatment, moving beyond previous symptom-based approaches like Acadia's Daybue.

• Neurogene has completed dosing of 25 female patients aged three years and older in its registrational Phase 3 Embolden trial for NGN-401, with data anticipated in the second half of 2027. Similarly, Taysha Gene Therapies completed dosing of 17 girls in its pivotal REVEAL trial for TSHA-102, aiming for a regulatory submission in the first half of 2027, marking significant progress towards market entry for these gene therapies.
• Experts and patient advocates express strong optimism that these gene therapies could fundamentally alter the disease's trajectory by targeting the root cause (MECP2 gene) rather than just managing symptoms. Early-stage trials for both NGN-401 and TSHA-102 have demonstrated 100% response rates, with every patient achieving multiple developmental milestones, suggesting a potentially dramatic and objective improvement over existing treatments.
• While both gene therapies utilize AAV delivery, they differ in administration; Taysha's TSHA-102 is delivered into the spinal cord, potentially offering easier administration, whereas Neurogene's NGN-401 is delivered directly into the brain. Neurogene previously abandoned a higher dose of NGN-401 due to a patient death attributed to the AAV vector, leading to the implementation of a biomarker protocol to enhance safety in subsequent trials.

Why New Rett Syndrome Treatments Are Urgently Needed

Current treatment for Rett syndrome remains largely symptomatic and fragmented despite substantial multisystem burden requiring continuous surveillance. Development of targeted molecular mechanism-based therapeutics is driven by improved genetic testing but constrained by rarity, heterogeneity, and the complexity of restoring MECP2 function.

• Trofinetide shows narrow efficacy with significant tolerability and practicality limits. Improvements were seen on Rett Syndrome Behaviour Questionnaire (RSBQ) and Clinical Global Impression-Improvement (CGI-I), with specific effect only on some subscales, i.e. General Mood subscale and Repetitive Face Movement subscale. No effects were documented on other subscales or on epilepsy, heart and bone-related symptoms, and trofinetide neither improved the Caregiver Top 3 Concerns Visual Analog Scale nor the Rett Motor Behavioral Assessment. The main adverse effects, severe enough to determine discontinuation, include diarrhea, vomiting, and consequent weight loss, with diarrhea reported in 53.2% and 80.0% and vomiting in 19.5% and 53.3% in long-term and younger-child studies, and odds ratio (OR): 3.17 for vomiting and OR: 18.51 for diarrhea in the trofinetide (200 mg) group compared to placebo. Use requires a very large amount per day, one bottle may last three days only, depending on weight, with limited duration of drug supplies and relatively high cost per bottle, and it is yet to be determined whether trofinetide may be curative if given early enough during brain development, or merely symptomatic if given to young adults.

• Single symptoms rely on non-specific drugs with suboptimal benefit-risk. Single symptoms, for instance, seizures or aggressive behaviors, are currently treated with drugs that have been developed for patients without the Rett Syndrome, leading to suboptimal efficacy and increased risk of adverse effects. Antiepileptic medications contributed most to treatment burden (14.3-33.0% for monotherapy), with other commonly used medications targeting sleep (melatonin, 7.7-30.0%), gastrointestinal symptoms (proton-pump inhibitors, 37.0-61.0%) and behavioral symptoms (anti-anxiety agents, 10.0-21.4%), reflecting reliance on symptom-directed therapies and highlighting the need for routine medication review, careful prescribing and longitudinal monitoring.

• Gene replacement and editing face dosage, delivery, and timing barriers. Both deficiency and excessive expression of MeCP2 are associated with severe neurological abnormalities, with overexpression leading to MECP2 duplication syndrome and overexpression-related toxicity, making simple viral vector-mediated replacement potentially unsafe. Current approaches need to overcome challenges of MeCP2 dosing, genotoxicity, transduction efficiencies and biodistribution, requiring precise cell- and dose-dependent regulation through cell-specific and endogenous promoters, miRNA-regulated elements, autoregulatory systems, and post-transcriptional control. Gene therapies have better outcomes when the brain is not the primary target, early intervention appears more critical with targeting the pre-symptomatic stage potentially preventing symptom pathology, while intervention at later stages may only clinically stabilise patients, and the timing of intervention and the administration route would be critical parameters for successful outcomes.

• Clinical development and care delivery remain fragmented. Given the diverse genetic landscape of RTT, correlations between RTT genotype and phenotypic improvements are not established, with clinical severity still very variable and caution recommended in using genotype-phenotype data in prognosis. Trials have been short, small, and largely in females, with recommendations for RCTs encompassing male patients with larger and longer cohorts. In practice, for the majority of patients the most frequent complications were not followed by the reference subspecialist, with only 15% followed by a pulmonologist despite apneas in 81%, only 33% followed by a gastroenterologist despite gastrointestinal symptoms in 63.5%, and only 25% followed by an orthopedist despite orthopedic issues in 78.8%, while about one quarter were not vaccinated.

REVEAL and Embolden: Designing Pivotal Rett Syndrome Gene Therapy Trials

Pivotal development in Rett syndrome (RTT) has centered on trofinetide, evaluated from exploratory phase 2 dose-escalation through the 12-week phase 3 LAVENDER trial and its long-term extensions LILAC/LILAC-2 and DAFFODIL in younger children. Supportive interventional studies have explored additional agents and non-pharmacologic approaches using disease-specific behavioral, global impression, and motor function scales.

NGN-401 Safety and the Rett Syndrome Gene Therapy Race

NGN-401 is an adeno-associated virus serotype 9 (AAV9) construct for self-regulated MECP2 gene therapy, identified as an optimal configuration following cellular and in vivo testing of the Expression Attenuation via Construct Tuning (EXACT) system. EXACT uses a self-contained, microRNA-based feed-forward loop that ensures more consistent transgene expression and protects against excessive expression. Through cell-based screening assays, the EXACT circuit modulated expression of full-length human MeCP2, with an EXACT-MECP2 construct exhibiting a narrower range of cellular protein abundance compared with a conventional construct. The degree of regulation by the EXACT circuit increased with higher transgene doses in vitro and in wild-type mice and mice modeling RTT.

Delivery of NGN-401 to neonatal male Mecp2 hemizygous mice via intracerebroventricular injection resulted in prolonged survival and amelioration of RTT-like phenotypes compared with vehicle-treated animals. NGN-401 was also well tolerated by female Mecp2 mice and healthy juvenile nonhuman primates, in contrast with a conventional construct, which caused toxicity. The results from these studies underpin a first-in-human pediatric trial of NGN-401 in RTT (ClinicalTrials.gov, NCT05898620).

Rett Syndrome: Gene Therapy's Pivotal Moment Approaches

The pharmaceutical landscape for Rett syndrome is on the cusp of a profound transformation, as Taysha Gene Therapies and Neurogene advance their gene therapies, TSHA-102 and NGN-401, towards regulatory submissions. This represents a significant leap from the current standard of care, which, while offering symptomatic relief, does not address the genetic root cause of this debilitating neurodevelopmental disorder.

Currently, trofinetide (Daybue) is the only approved pharmacologic treatment, demonstrating efficacy in improving core symptoms such as communication and behavior, as evidenced by improvements in scales like the Rett Syndrome Behaviour Questionnaire (RSBQ) and Clinical Global Impression-Improvement (CGI-I). However, its use is associated with a high incidence of gastrointestinal adverse events, primarily diarrhea and vomiting, which can lead to treatment discontinuation. While trofinetide has established a real-world presence, particularly among younger, specialist-managed patients, a substantial proportion of eligible individuals remain untreated, highlighting an ongoing unmet need.

Gene therapies, in contrast, aim to deliver a functional copy of the MECP2 gene, offering the potential for a one-time, disease-modifying treatment. The preclinical and early clinical data for TSHA-102 and NGN-401 are highly encouraging, with reports of 100% response rates and patients achieving developmental milestones. This suggests a potential for more comprehensive and sustained improvements than symptomatic approaches. A critical aspect of these gene therapy designs is the incorporation of self-regulating expression systems, such as miRARE in TSHA-102 and EXACT in NGN-401. This innovation directly addresses the known risk of MECP2 overexpression, which can lead to severe neurological deficits, ensuring a more controlled and potentially safer therapeutic window.

However, the journey ahead is not without considerations. The long-term safety and durability of these novel gene therapies remain to be fully elucidated, with pivotal trial data anticipated in 2027. The chronic nature of Rett syndrome necessitates sustained benefit without unforeseen late-onset adverse events. Furthermore, these gene therapies will need to demonstrate a significantly superior benefit-risk profile compared to trofinetide to justify their potentially higher cost and novel risk profile, ultimately reshaping treatment pathways and patient expectations.